Orchestra BioMed Holdings, Inc. Ordinary Shares
OBIOOrchestra BioMed Holdings, Inc. is a medical device company focused on developing and commercializing innovative solutions for cardiovascular and other medical conditions. The company leverages a combination of proprietary technologies and strategic partnerships to bring minimally invasive and durable devices to market. Its portfolio includes products aimed at improving treatment outcomes and patient quality of life.
Company News
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced its inclusion in the Russell 3000 Index and Russell 2000 Index following the 2026 Russell indexes reconstitution effective June 26, 2026. The biomedical company develops AVIM Therapy for hypertension in collaboration with Medtronic and Virtue SAB for atherosclerotic artery disease, both und...
Orchestra BioMed (OBIO) announced its participation in two major institutional investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference (March 3rd) and the Barclays 28th Annual Global Healthcare Conference (March 11th). Management will conduct fireside chats and one-on-one investor meetings at both events.
Orchestra BioMed initiated a pivotal U.S. clinical trial comparing its Virtue Sirolimus AngioInfusion Balloon to a paclitaxel-coated balloon for treating coronary in-stent restenosis, with 740 patients expected to be enrolled across 75 centers by mid-2027.
Orchestra BioMed presented clinical data showing AVIM therapy can sustainably reduce blood pressure in patients, with effects that are reversible and reproducible upon reactivation after a washout period.
Orchestra BioMed received FDA approval to expand patient eligibility for its BACKBEAT study, potentially increasing the eligible patient pool by over 24-fold and supporting its mid-2026 enrollment target for AVIM therapy in treating uncontrolled hypertension.
